TriangleNCT03241745 · OUTCOME
Progression-Free Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- 97.5% Confidence Interval
- Time frame
- at 24 weeks
What was measured
will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Groups in this outcome
Nivolumab
Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first. Nivolumab: Nivolumab 480 mg IV once every 4 weeks
| Group | Source count |
|---|---|
| Nivolumab | 35 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Nivolumab | 64.7 | Not reported | 46.5 | 100 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 46.5
- upper Limit
- 100
- value
- 64.7
- denoms
- counts
- group Id
- OG000
- value
- 35
- units
- Participants
- description
- will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
- dispersion Type
- 97.5% Confidence Interval
- groups
- description
- Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first. Nivolumab: Nivolumab 480 mg IV once every 4 weeks
- id
- OG000
- title
- Nivolumab
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- at 24 weeks
- title
- Progression-Free Survival
- type
- PRIMARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice